CureDuchenne Webinar: COVID-19 Vaccines – What the Duchenne Community Needs to Know

CureDuchenne’s webinar, COVID-19 Vaccines: What the Duchenne Community Needs to Know, was an opportunity for the Duchenne community to get reliable information on COVID-19 vaccines. A panel of experts from reputable hospitals, the FDA, CDC, and Pfizer offered specific insight on the implications of these vaccines for carriers and those living with Duchenne.

Considering the unprecedented speed at which these vaccines were developed and approved, general concerns about safety and efficacy are common. These apprehensions were addressed and quelled straight away by the panel, who expressed resounding support for getting vaccinated. In general, risks for carriers and those living with Duchenne were regarded as far higher from contracting COVID-19 than from getting vaccinated:

“If somebody offers you the vaccine, say yes. Even if you don’t think you’re ready, or you deserve it, take it if it’s offered.

– Dr. Kathy Mathews, MD

Panelists also fielded numerous critical questions specific to the Duchenne community: how the vaccines might impact clinical trial participants, whether Duchenne treatments impact the vaccine’s effectiveness, how the FDA and drug companies are approaching vaccines for those under 16, and more.

Don’t miss this opportunity to get reliable information straight from the source. Every family, living with Duchenne or not, will benefit from the information given by the experts. You can watch the webinar on-demand at the link below.

Looking for more information?

Helpful COVID-19 resources can be found here:


Peter Marks, MD, PhD
Director of FDA Center for Biologics Evaluation and Research

Georgina Peacock, MD, MPH, FAAP
Director of Division of Human Development and Disability, CDC National Center on Birth Defects and Developmental Disabilities

William Gruber, MD
Senior Vice President, Vaccine Clinical Research and Development, Pfizer, Inc.

Oscar “Hank” Mayer, MD
Director of Pulmonary Function Laboratory, Children’s Hospital of Philadelphia

Kathy Mathews, MD
Professor of Pediatrics and Neurology, Vice Chair for Clinical Investigation, Department of Pediatrics, University of Iowa

Debra Miller
Founder and CEO, CureDuchenne


Michael Kelly, PhD
Chief Scientific Advisor, CureDuchenne

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.